The Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, estimated at USD 25,331.1 Mn in 2025, is expected to exhibit a CAGR of 20.13% and reach USD 91,456.5 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Among product Diagnostics segment held dominant position in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market in 2025, accounting for 67.0% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.
Market Trends:
Increasing awareness about NASH is one of the key trends expected to boost growth of the global biosurgery market. With the increase in awareness among people, demand for novel therapeutics and diagnostics is also increasing with a rapid pace. International NASH Day is an initiative started by the Global Liver Institute to raise awareness of the growing worldwide epidemic of NAFLD and its more advanced form, NASH. There are an increasing number of awareness programs for the disease to help patients, healthcare professionals, and researchers better diagnose/treat NASH. This trend is expected to continue over the forecast period, driving the market growth.
Competitive Landscape:
Major players operating in the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market include Novartis AG, Allergan Plc., Viking Therapeutics, Merck & Co., Zydus Cadila, Novo Nordisk A/S, GENFIT SA, Gilead Sciences Inc., Galmed Pharmaceuticals, Madrigal Pharmaceuticals, and Intercept Pharmaceuticals Inc., among others.
Recent Developments:
In March 2025, Madrigal Pharmaceuticals, Inc. announced that it has initiated its Phase 3 trial in non-alcoholic steatohepatitis (NASH) with its once daily, oral thyroid hormone receptor beta selective agonist, MGL-3196 (resmetirom). This double-blind, placebo-controlled study will be conducted at more than 150 sites in the United States and the rest of the world.
In March 2025, Genfit started trading on NASDAQ, and issued new shares in its existing Euronext Paris listing. The company raised a total of EUR 120 million (about US$ 135 million).
In February 2025, Intercept Pharmaceuticals, Inc. announced positive results from its pivotal Phase 3 REGENERATE study of obeticholic acid (OCA) in patients with liver fibrosis owing to non-alcoholic steatohepatitis (NASH).
In October 2025, Novartis entered into a clinical development agreement with Pfizer, which will include a study combining tropifexor and one/more Pfizer compounds for the treatment of NASH.
Contact Us